ABBOTT-CLOPIDOGREL TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

CLOPIDOGREL (CLOPIDOGREL BISULFATE)

MAH:

ABBOTT LABORATORIES, LIMITED

ATC_code:

B01AC04

INN:

CLOPIDOGREL

dosage:

75MG

pharmaceutical_form:

TABLET

composition:

CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG

administration_route:

ORAL

units_in_package:

100/500

prescription_type:

Prescription

therapeutic_area:

PLATELET AGGREGATION INHIBITORS

leaflet_short:

Active ingredient group (AIG) number: 0134440001; AHFS:

authorization_status:

CANCELLED POST MARKET

authorization_date:

2015-12-31

SPC

_ _
_Abbott-Clopidogrel Product Monograph _
_Page 1 of 52 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ABBOTT-CLOPIDOGREL
Clopidogrel Tablets USP
75 mg clopidogrel, as clopidogrel bisulfate
Platelet Aggregation Inhibitor
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Revision:
November 27, 2014
Submission Control No.: 179756
_ _
_Abbott-Clopidogrel Product Monograph _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
.........................................................